Exactech (EXAC) Given Coverage Optimism Rating of 0.08

Headlines about Exactech (NASDAQ:EXAC) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Exactech earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.8548250073686 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern’s analysis:

Exactech (NASDAQ:EXAC) traded up $0.10 during midday trading on Thursday, hitting $41.85. 126,500 shares of the company traded hands, compared to its average volume of 63,958. The company has a current ratio of 4.08, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. Exactech has a twelve month low of $23.30 and a twelve month high of $42.75. The company has a market capitalization of $599.79, a PE ratio of 34.50, a PEG ratio of 3.58 and a beta of 1.04.

Exactech (NASDAQ:EXAC) last announced its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). The business had revenue of $61.40 million for the quarter, compared to the consensus estimate of $61.78 million. Exactech had a return on equity of 7.22% and a net margin of 0.18%. sell-side analysts predict that Exactech will post 1.29 earnings per share for the current year.

EXAC has been the subject of several research reports. Zacks Investment Research cut shares of Exactech from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. BidaskClub cut shares of Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Gabelli cut shares of Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird cut shares of Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research note on Monday, October 23rd. Finally, Sidoti cut shares of Exactech from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $42.00.

COPYRIGHT VIOLATION WARNING: “Exactech (EXAC) Given Coverage Optimism Rating of 0.08” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/11/23/exactech-exac-given-coverage-optimism-rating-of-0-08.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Insider Buying and Selling by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply